Institute of Pharmaceutical Medicine ECPM www.ecpm.ch

Grüne Wohlen bei Bern http://www.grüne-wohlen.ch/

Midwife Lisanne Matter  http://www.hebamme-lisanne.ch/

Solarkraftwerk Wohlen http://www.sokw.ch/

Swiss Group for Clinical Cancer Research SAKK www.sakk.ch

Fr

21

Apr

2017

Diving Egypt

Mo

10

Apr

2017

Updated health economic analysis Palbociclib

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available.

 

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-7. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

0 Kommentare

So

09

Okt

2016

Logbook Greece 2016

Logbook now online